Product
  • Product
  • Supplier
  • Inquiry

    EN

    Home > News >

    Pharmaceutical

    banner
    After 'initial shock,' generics supply chain likely to weather COVID-19 blows

    After 'initial shock,' generics supply chain likely to weather COVID-19 blows

    The specter of global drug shortages looms large amid the coronavirus pandemic. But so far, the supply chain is holding steady and prices are going up—in the generic drug business, at least.
    hydroxychloroquine

    2020-04-09

    Chinese APIs flowing but India ban hinders U.S. approval of hydroxychloroquine

    Chinese APIs flowing but India ban hinders U.S. approval of hydroxychloroquine

    he production of Chinese active pharmaceutical ingredients (APIs) slipped by 10% to 20% during the early days of the COVID-19 outbreak in China but is quickly recovering. The bottleneck in the global supply chain for APIs is now shipping
    API hydroxychloroquine

    2020-04-09

    Yanan Petrochemical converted polypropylene medical non-woven fabric material

    Yanan Petrochemical converted polypropylene medical non-woven fabric material

    On March 30, the polypropylene plant of Yan'an Petrochemical Plant successfully converted to a new grade of polypropylene fiber material (PPH-Y38), marking the plant's ability to mass-produce special materials for medical non-woven fabrics and promoting t
    polypropylene medical

    2020-04-09

    48 listed pharmaceutical companies report their achievements

    48 listed pharmaceutical companies report their achievements

    After the annual report release tide of global large multinational pharmaceutical enterprises, the industry recently ushered in the annual report intensive disclosure period of local pharmaceutical listed enterprises.
    Biopharma's Future: Made in China

    Biopharma's Future: Made in China

    But now the country’s economic growth is slowing, its leaders are looking to the next phase – moving from being a low-cost location for manufacturing, to an economy developing its own intellectual property-based products – including innovative medicines.
    Biopharma China

    2020-04-08

    Gilead turbocharges production of COVID-19 hopeful remdesivir

    Gilead turbocharges production of COVID-19 hopeful remdesivir

    Gilead Sciences' remdesivir has courted high hopes as a potential treatment for COVID-19—so high, in fact, that the company previously had to shut down emergency access to the drug.
    Gilead remdesivir

    2020-04-08

    Johnson & Johnson announces a lead vaccine candidate for COVID-19

    Johnson & Johnson announces a lead vaccine candidate for COVID-19

    Johnson & Johnson (NYSE: JNJ) (the Company) announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020
    Johnson & COVID-19

    2020-04-08

    The pharmaceutical industry is still growing rapidly under the epidemic

    The pharmaceutical industry is still growing rapidly under the epidemic

    China's pharmaceutical industry revenue steady growth. However, affected by the epidemic this year, the profits of Industrial Enterprises above designated size decreased by 38.3% year-on-year from January to February, while the profits of pharmaceutical
    pharmaceutical

    2020-04-08

    People on steroids for chronic illness may be more at risk of COVID-19

    People on steroids for chronic illness may be more at risk of COVID-19

    Glucocorticoids are frequently a medication doctors prescribe for chronic inflammatory diseases, such as asthma, chronic obstructive pulmonary disease, and inflammatory bowel disease.
    steroid hormone COVID-19

    2020-04-07

    Bill Gates is funding factories for 7 potential coronavirus vaccines

    Bill Gates is funding factories for 7 potential coronavirus vaccines

    “Our early money can accelerate things,” Gates said. The foundation is picking the seven “most promising” vaccine constructs and will help fund factories for all seven, he added, “even though we’ll end up picking at most two” to actually deploy.
    Clues to COVID-19's vulnerability emerge from an antibody

    Clues to COVID-19's vulnerability emerge from an antibody

    An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the new coronavirus at the root of COVID-19, according to a study from scientists at Scripps Research.
    COVID-19 SARS

    2020-04-07

    Suggestions
    Email:
    Message:
    Send Message